Département de Biologie Cellulaire et Moléculaire, Faculté des Sciences Biologiques, Université des Sciences et de la Technologie Houari, Boumediène, Alger, Algérie.
Arch Med Res. 2010 Apr;41(3):215-20. doi: 10.1016/j.arcmed.2010.03.008.
The etiology of atherosclerosis is multifactorial. Genetic and environmental factors are involved in the development of atherosclerosis. Human arylamine N-acetyltransferase 2 (NAT2) is an important metabolizing enzyme that exhibits genetic polymorphisms and modifies individual response and/or toxicity to many xenobiotics. We undertook this study to investigate the NAT2 polymorphisms in patients with atherosclerosis.
Genotyping for NAT2 alleles was performed using polymerase chain reaction-restriction fragment-length polymorphism (PCR-RFLP) in 285 Algerian patients with atherosclerosis and 286 controls.
There was no association between NAT2 polymorphisms and atherosclerosis risk. However, the haplotype NAT2(*)5F decreased susceptibility to the disease (p = 0.005, OR = 0.55, 95% CI = 0.37-0.84). The frequency of the slow acetylator phenotype was approximately 50% in both cases and controls.
These results suggest that NAT2 polymorphisms may not be involved in the pathogenesis of atherosclerosis.
动脉粥样硬化的病因是多因素的。遗传和环境因素参与动脉粥样硬化的发生。人类芳香胺 N-乙酰基转移酶 2（NAT2）是一种重要的代谢酶，具有遗传多态性，可改变个体对许多外源性物质的反应和/或毒性。我们进行这项研究是为了探讨动脉粥样硬化患者中 NAT2 多态性。
采用聚合酶链反应-限制性片段长度多态性（PCR-RFLP）方法对 285 例阿尔及利亚动脉粥样硬化患者和 286 例对照者的 NAT2 等位基因进行基因分型。
NAT2 多态性与动脉粥样硬化风险之间没有关联。然而，NAT2(*)5F 单倍型降低了患病风险（p=0.005，OR=0.55，95%CI=0.37-0.84）。在病例组和对照组中，缓慢乙酰化表型的频率均约为 50%。
这些结果表明，NAT2 多态性可能与动脉粥样硬化的发病机制无关。
